Skip to Content

Label Changes for:

Xyzal (levocetirizine dihydrochloride) oral solution and tablets

March 2011

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011




 Postmarketing Experience
  • vomiting, dysuria, blurred vision, angioedema, paraesthesia, dizziness